The Biospecimen Extraction Resource (BER) is a centralized laboratory for standardized, high-quality, reasonably-priced DMA and RNA extraction from various sources. The BER performs PCR-based analysis of these nucleic acids including pyrosequencing for genotyping of single nucleotide polymorphisms and for detection of CpG island methylation. In addition, the BER consults with non-laboratory-based investigators to help them accomplish their laboratory-based goals related to the facility. The BER is located in the newlyconstructed Basic Science Research Building (BSRB). The BER uses state-of-the-art instrumentation including the Autopure LS automated DMA extraction machine and the PSQ pyrosequencer. The BER has an 8-member oversight committee. A website provides information about services, guidelines for preparing samples for DMA extraction, and other procedures performed by the facility, as well as forms to be completed when requesting service. In the current grant period, the BER was used by 35 different investigators from 17 programs with 98% of usage coming from investigators having peer-reviewed funding. Most of the DMA extractions are from human peripheral blood leukocytes or saliva. An increase of over 400% has been seen over the past year compared to those extracted in 2002. The source of funds for the proposed operating budget of the BER for year 33 (July 1, 2008-June 30, 2009) is 14% from TexGen, 53% from user fees, and 34% from the CCSG. Future plans include continued expansion to large projects such as TexGen, the """"""""LBJ Patient History Database-Serum/DNA Bank"""""""" and the """"""""Repository of Tissue and Blood on Patients in the Cancer Prevention Center.""""""""

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-36
Application #
8310870
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
36
Fiscal Year
2011
Total Cost
$79,349
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :
Patel, V K; Lamothe, B; Ayres, M L et al. (2018) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32:920-930
Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid et al. (2018) Phase 3 results for vosaroxin/cytarabine in the subset of patients ?60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica 103:e514-e518
Assi, Rita; Kantarjian, Hagop M; Kadia, Tapan M et al. (2018) Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124:2758-2765
Yam, Clinton; Murthy, Rashmi K; Valero, Vicente et al. (2018) A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36:299-306
Lacourt, Tamara E; Vichaya, Elisabeth G; Escalante, Carmen et al. (2018) An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology 96:109-117
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433

Showing the most recent 10 out of 12418 publications